IMMUNIQUE

Name

IMMUNIQUE

Legal name

이뮤니크 주식회사 (IMMUNIQUE, Inc.)

Website

https://immunique.co.kr

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Cell therapy therapeutics
• Regulatory T cells
• Autoimmune disease treatments
• Cord blood immunotherapy
• Biopharmaceutical R&D

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharmaceutical Development and Commercialization: IMMUNIQUE is a pre-revenue R&D company developing cell therapy products. Revenue will be generated through commercialization of Treg cell therapeutics for autoimmune diseases and immune-related disorders once clinical trials are completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IMMUNIQUE develops cord blood-derived regulatory T cell (Treg) therapeutics for treating intractable autoimmune diseases and immunodeficiency-related conditions. The portfolio includes polyclonal Treg products (IMQ101-GvHD for graft-versus-host disease, IMQ101-AA for aplastic anemia) and gene-edited CAR-Treg candidates (IMQ301/302) that target specific autoimmune diseases. The company is a pre-revenue R&D-stage biopharmaceutical firm focused on advancing these cell therapies through clinical trials toward commercialization.

Product overview

IMMUNIQUE develops cord blood-derived immune cell therapeutics, specifically focusing on regulatory T cell (Treg) based treatments. The product portfolio includes Polyclonal Treg Therapeutics (IMQ101-GvHD, IMQ101-AA) as off-the-shelf allogeneic treatments, and CAR-Treg Therapeutics (IMQ301/302) for targeted autoimmune disease applications. The company leverages cord blood as a superior source of immune cells with lower HLA expression compared to bone marrow or peripheral blood, enabling broader allogeneic use.

Differentiator

Problem solved

Functional benefit

Products and services

• IMQ101-GvHD Regulatory T cell (Treg) therapy candidate for Graft-versus-Host Disease (GvHD), a complication occurring after allogeneic hematopoietic stem cell transplantation where donor T cells attack the recipient's normal cells. Affects 25-40% of HSCT patients with no effective treatment beyond steroids.
• IMQ101-AA Regulatory T cell therapy candidate for Aplastic Anemia (AA), a rare autoimmune disorder caused by bone marrow failure where cytotoxic T cells attack self-hematopoietic stem cells. Current standard treatment (immunosuppressive drugs) has 60-70% efficacy with long-term complications; stem cell transplantation carries 10% mortality risk.
• IMQ301/302 CAR-Treg (Chimeric Antigen Receptor Regulatory T Cell) therapeutic candidates for autoimmune diseases, designed to directly target cells causing autoimmune reactions including lupus, rheumatoid arthritis, multiple sclerosis, and organ-specific autoimmune conditions without the side effects of conventional CAR-T therapies.
• Polyclonal Treg Therapeutics Off-the-shelf allogeneic cord blood-derived regulatory T cell therapeutic platform for various autoimmune diseases including GvHD, aplastic anemia, ankylosing spondylitis, and lupus. Features high suppression activity against cytotoxic T cells and anti-inflammatory cytokine production without requiring patient-specific cells.
• CAR-Treg Therapeutics Gene-edited regulatory T cell therapeutics using chimeric antigen receptors (CAR) inserted into Treg cell surfaces to target specific organs or tissues for autoimmune disease treatment. Utilizes IMMUNIQUE's proprietary CAR-Platform with disease-specific scFv antibody fragments.

Quantifiable outcome

• 60-70% treatment efficacy with standard immunosuppressive therapy (ATG)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Ewha Womans University Mokdong Hospital (이대목동병원)coreStrategic or Co-development Partner · 9 September 2025Clinical collaboration for aplastic anemia Treg cell therapy: basic and non-clinical research, clinical trial planning and execution, regulatory support, academic publication and IP rights, technology and research exchange. Hospital will provide clinical expertise while IMMUNIQUE contributes cell therapy technology.
• KINE Sciences (카인사이언스)minorStrategic or Co-development Partner · 1 November 2023Joint research and development collaboration for regenerative medicine technologies, focusing on advanced cell therapy development.
• Ewha Womans University Mokdong Hospital (공동연구기관: 이화여대 목동병원)coreStrategic or Co-development Partner · 1 April 2023Selected as participating company in government-funded project for regenerative medical technology development (범부처 재생의료 기술 개발 국책과제), collaborating with Ewha Womans University Mokdong Hospital.
• Hanyang University Institute for Rheumatology Research (한양대학교류마티즘연구원)coreStrategic or Co-development Partner · 14 March 2023Joint R&D project collaboration for autoimmune disease treatments: basic research material exchange, cord blood-derived Treg cell provision, basic research and animal studies. Leverages both parties' research infrastructure for regenerative medicine research.
• MEDIPOST (메디포스트)coreStrategic or Co-development Partner · 1 April 2021Parent company and strategic partner providing 30 billion KRW initial investment. MEDIPOST is Korea's No. 1 cord blood storage company and stem cell therapeutics developer (commercialized Kartistem for osteoarthritis). IMMUNIQUE leverages MEDIPOST's cord blood resources, stem cell technology expertise, and commercialization know-how. Parent company CEO Yang Yun-sun and R&D head Oh Won-il serve as advisory board members.
• MD Anderson Cancer Center (미국 엠디앤더슨암센터)minorStrategic or Co-development Partner · 1 January 2018Initial collaboration initiated at 2018 international seminar in Texas where MD Anderson professor proposed joint research on cord blood-derived Treg cell immunotherapy. This collaboration opportunity led to IMMUNIQUE's founding. The US-based company founded by this professor was later acquired by a Chinese company.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sonoma Biotherapeutics: Clinical-stage Treg cell therapy company developing engineered regulatory T cells for autoimmune and inflammatory diseases. Most directly comparable peer with a similar Treg-focused platform and similar indication targeting.
• Quell Therapeutics: UK-based cell therapy company developing engineered Treg cell therapies for autoimmune diseases and preventing organ transplant rejection. Competes directly with IMMUNIQUE in the allogeneic Treg space with significant venture funding.
• Coya Therapeutics: Clinical-stage biotechnology company developing Treg-based therapies for neurodegenerative and autoimmune diseases. Competes in the Treg cell therapy space with overlapping autoimmune indications.
• Egle Therapeutics: French biotechnology company developing regulatory T cell-based immunotherapies for autoimmune diseases and cancer. Directly comparable as a Treg-focused biotech targeting similar indications.
• Abata Therapeutics: Clinical-stage company developing Treg cell therapies for autoimmune diseases, with initial focus on multiple sclerosis. Founded by researchers from Seattle, comparable as a next-generation Treg therapy developer.

Emerging players

• Kyverna Therapeutics: Clinical-stage cell therapy company developing CAR-T therapies for autoimmune diseases, particularly B cell-driven conditions like lupus. Comparable as a next-generation engineered cell therapy for autoimmune indications, though focused on CAR-T rather than CAR-Treg.
• Cartesian Therapeutics: Clinical-stage company developing engineered cell therapies including Treg products for autoimmune disease. RNA cell therapy platform with overlapping approach to autoimmune disease treatment.
• TR1X: Early-stage biotechnology company developing allogeneic engineered Treg cell therapies for autoimmune and inflammatory diseases. Comparable as a next-generation Treg therapy developer with similar scientific approach.
• Cellenkos: Clinical-stage company developing cord blood-derived regulatory T cell therapies. Directly comparable in using cord blood as a Treg source, though focused on different delivery approaches.

Broad incumbents

• Medipost: Parent company and Korea's leading cord blood bank and stem cell therapy company. Commercialized Cartistem for osteoarthritis. Most directly relevant Korean peer with established cell therapy commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMMUNIQUE